COMMUNIQUÉS West-GlobeNewswire

Du massage intelligent au bien-être proactif : SKG élargit sa gamme de dispositifs de santé portables à l’occasion de l’IFA 2026
08/09/2026
La présentation à Berlin associe la technologie de massage portable de SKG à la récupération, à l’accompagnement de l’entraînement et au suivi préventif de la santé BERLIN, 08 sept. 2026 (GLOBE NEWSWIRE) -- SKG Health [...]
Transactions in connection with share buy-back program
08/09/2026
Company announcement no. 34 - 26 08 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease
08/09/2026
Sabrina Kuttruff-Coqui appointed Chief Executive Officer, Joachim Koch appointed Chief Scientific and Development Officer and Andreas Muehler joining as Chief Medical Officer Expanded leadership team brings decades of [...]
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
08/09/2026
LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
MediciNova to Participate in Two Investor Conferences in September
08/09/2026
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
Notice to Convene an Extraordinary General Meeting of Genmab A/S
08/09/2026
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be [...]
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
08/09/2026
U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, [...]
UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment
08/09/2026
LOR, the first approval-stage drug candidate with disease-modifying potential for osteoarthritis, is now under assessment in the United Kingdom, with a submission to the European Medicines Agency planned for later this [...]
Prana Therapies Announces Positive Phase 1 Results for PRA-216, a Novel IL-4Rα/TSLP Bispecific Antibody, Supporting Its Potential Best-in-Disease Profile and Providing the First Clinical Validation of Prana’s INSPIRE Multispecific Platform
08/09/2026
Rapid, deep, and durable pharmacodynamic activity demonstrated across key Type 2 inflammatory biomarkers, including pSTAT6, TARC, eosinophils, and IgE Extended half-life and 85% subcutaneous bioavailability support the [...]
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
08/09/2026
Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels ACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE [...]
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
08/09/2026
Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE 87% attack rate reduction versus placebo observed in people with HAE [...]
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
08/09/2026
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence [...]
Rapid Nutrition Reports 227.5% H1 Revenue Growth as Group Enters Transformational Second Half
08/09/2026
Completion of the HealthShop+ acquisition shortly before period-end establishes a materially enlarged operating and revenue base for H2 and beyond LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext [...]
Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial
08/09/2026
Single ascending dose (SAD) portion completed in healthy volunteers, with dose-proportional pharmacokinetics (PK), clear evidence of ERAP1 target engagement, and no safety or tolerability concerns observed GRWD0715 [...]
Infex Therapeutics presents new Phase IIa data for RESP-X at ERS Congress 2026, providing further evidence on exploratory efficacy endpoints supporting progression to later stage development
08/09/2026
Pa -positive NCFB patients experienced a significant reduction in annualised exacerbation rate from 3.4 in the prior 12 months to 1.2 on RESP-X treatment Only one exacerbation meeting the Hill/EMBARC criteria was [...]
Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer
08/09/2026
Dr Ambarkhane brings proven 20+ year track record advancing innovative cancer therapies through clinical development and regulatory approval Appointment strengthens Cytospire's executive leadership team as the Company [...]
PannTheraPi obtient l'approbation de l’ANSM pour l’entrée en Phase 2a de PTI5803 dans la dysplasie corticale focale
08/09/2026
L’étude de Phase 2a évaluera PTI5803, un traitement first-in-class ciblant le canal Pannexin1, chez des patients atteints de dysplasie corticale focale pharmacorésistante, une forme rare et sévère d’épilepsie Nîmes, le [...]

Pages